AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs. The Company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C.
Type
Public
HQ
North Chicago, US
Founded
2013
Size (employees)
29,000 (est)
Website
abbvie.com
AbbVie was founded in 2013 and is headquartered in North Chicago, US
Report incorrect company information

Key People/Management at AbbVie

Richard Gonzalez

Richard Gonzalez

Chairman of the Board and Chief Executive Officer
Carlos Alban

Carlos Alban

Executive Vice President, Commercial Operations
Timothy Richmond

Timothy Richmond

Senior Vice President, Human Resources​
Azita Saleki-Gerhardt

Azita Saleki-Gerhardt

Senior Vice President, Operations
Karen Hale

Karen Hale

Vice President, Chief Ethics and Compliance Officer
Wulff-Erik von Borcke

Wulff-Erik von Borcke

President, Pharmacyclics
Show more

AbbVie Office Locations

AbbVie has offices in Singapore, Campoverde, Sligo, San Francisco and in 12 other locations
North Chicago, US (HQ)
1 Waukegan Rd
Cambridge, US
200 Sidney St
Barceloneta, PR
PR-2
Show all (16)
Report incorrect company information

AbbVie Financials and Metrics

AbbVie Revenue

Embed Graph
AbbVie's revenue was reported to be $25.64 b in FY, 2016 which is a 12.2% increase from the previous period.
USD

Revenue (Q2, 2018)

16.2 b

Gross profit (Q2, 2018)

12.4 b

Gross profit margin (Q2, 2018), %

76.2%

Net income (Q2, 2018)

4.8 b

EBIT (Q2, 2018)

5.7 b

Market capitalization (16-Aug-2018)

148.7 b

Closing stock price (16-Aug-2018)

98.2

Cash (30-Jun-2018)

3.5 b

EV

148.7 b
AbbVie's current market capitalization is $148.7 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

18.8 b20 b22.9 b25.6 b

Revenue growth, %

6%15%12%

Cost of goods sold

4.6 b4.4 b4.5 b5.8 b

Gross profit

14.2 b15.5 b18.4 b19.8 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

4.7 b4.6 b4.9 b5 b5 b5.5 b5.9 b6 b6.5 b6.4 b6.5 b6.9 b7.9 b16.2 b

Cost of goods sold

1.1 b1.1 b1.1 b1.1 b942 m916 m1.2 b1.4 b1.4 b1.5 b1.6 b1.5 b1.9 b3.9 b

Gross profit

3.6 b3.5 b3.8 b3.9 b4.1 b4.6 b4.8 b4.6 b5 b4.9 b4.9 b5.4 b6 b12.4 b

Gross profit Margin, %

77%76%77%78%81%83%80%77%78%77%75%78%76%76%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

9.6 b8.3 b8.4 b5.1 b

Accounts Receivable

3.9 b3.7 b4.7 b4.8 b

Inventories

1.2 b1.1 b1.7 b1.4 b

Current Assets

17.8 b16.1 b16.3 b16.2 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

9 b8.1 b9.1 b7.7 b7.9 b7.4 b9.2 b7.6 b6.3 b6.2 b4.7 b6.1 b9 b3.5 b

Accounts Receivable

3.8 b3.7 b3.7 b3.6 b4.2 b4.4 b4.6 b4.8 b5 b5 b4.7 b4.9 b5.8 b5.8 b

Inventories

1.2 b1.1 b1 b1 b1 b1.6 b1.8 b1.8 b1.8 b1.6 b1.4 b1.6 b1.7 b1.6 b

Current Assets

16.5 b17.3 b17.8 b17.6 b15.4 b16.9 b17.9 b16.6 b16.8 b16.3 b15.5 b17 b20.4 b13.8 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

4.1 b1.8 b5.1 b6 b

Inventories

(56 m)(203 m)(434 m)(38 m)

Accounts Payable

(426 m)(193 m)1.5 b(1.2 b)

Cash From Operating Activities

6.3 b3.5 b7.5 b7 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

964 m980 m1.1 b2.6 b1 b2.4 b3.6 b1.4 b3 b4.6 b1.7 b3.6 b2.8 b4.8 b

Depreciation and Amortization

593 m158 m348 m575 m268 m557 m861 m374 m753 m445 m888 m

Inventories

20 m(75 m)(160 m)(446 m)19 m(160 m)28 m71 m1 m(71 m)(191 m)

Accounts Payable

(1 m)188 m409 m1.3 b42 m89 m(975 m)(266 m)(530 m)191 m12 m
USDY, 2018

EV/EBIT

26.2 x

Revenue/Employee

559 k

Financial Leverage

-18.3 x
Show all financial metrics

AbbVie Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Stem CentRx (156)April 28, 2016$5.80 b
Report incorrect company information

AbbVie Online and Social Media Presence

Embed Graph
Report incorrect company information

AbbVie News and Updates

Tolero Pharmaceuticals Announces Clinical Research Collaboration with AbbVie for Acute Myeloid Leukemia Trial

SALT LAKE CITY, Aug. 17, 2018 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for hematologic and oncologic diseases, has entered into a clinical research collaboration with AbbVie, a research-based global...

Atopic Dermatitis (AD) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, and Forecasts 2018 To 2026

Global Atopic Dermatitis (AD) Treatment Market Is Expected To Reach US$ 7.66 Bn By 2025 Posted via Industry Today. Follow us on Twitter @IndustryToday

Glioblastoma Multiforme Market Size, Share, Outlook and Forecast to 2018 | Leading Players are AbbVie, Inc., Activartis GmbH, Agenus Inc., Arog Pharmaceuticals, Inc.

Glioblastoma multiforme (GBM) belongs to a group of brain tumors known as gliomas that grows from a type of brain cell called a glial cell. It is the most common primary brain tumor in adults and also the most aggressive form of brain tumor. According to U.S. National Cancer Institute, GBM is consid…

Merck’s 60% price cut for hepatitis C drug nets company a big sales opportunity

The major price reduction will make the drug the “low cost leader” in hepatitis C next year, an Express Scripts spokesperson says.

CytomX to Present at the 2018 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, will present …

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AbbVie Inc. (ABBV)

NEW YORK, July 31, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV). Such investors are encouraged to obtain additional information and assist...
Show more
Report incorrect company information

AbbVie Company Life and Culture

Report incorrect company information